Nutrigenomics: Concepts and applications to pharmacogenomics and clinical medicine

Pharmacogenomics

Volumn 8, Issue 4, 2007, Pages 369-390

  Kaput, Jim ^a,b   Perlina, Alla ^c   Hatipoglu, Betul ^d   Bartholomew, Amelia ^a   Nikolsky, Yuri ^c,e  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GeneGo   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

^e NONE   (United States)

Author keywords

15 dOH; Dietary lipids; Nutrigenomics; Pharmacogenomics; Prostaglandin J2; Rosiglitazone; Type 2 diabetes

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; EXENDIN 4; GENISTEIN; GLIBENCLAMIDE; HYPERFORIN; INSULIN; LACTASE; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE; SULFONYLUREA;

BINDING AFFINITY; CHRONIC DISEASE; CLINICAL MEDICINE; COMBINATION CHEMOTHERAPY; DIET THERAPY; DIETARY INTAKE; DISEASE COURSE; DISEASE SEVERITY; ENERGY; EPISTASIS; FOOD COMPOSITION; GENE EXPRESSION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC VARIABILITY; HUMAN; HUMAN GENOME; LIFESTYLE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRIENT; NUTRIGENOMICS; PATHOGENESIS; PHARMACOGENOMICS; PHENOTYPE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 34247175019     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.4.369     Document Type: Review

References (204)

1. Kolonel LN, Altshuler D, Henderson BE: The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat. Rev. Cancer 4(7), 519-527 (2004).
2. Kaput J, Rodriguez RL: Nutritional genomics: the next frontier in the postgenomic era. Physiol. Genomics 16(2), 166-177 (2004).
3. Nutritional Genomics. Discovering the Path to Personalized Nutrition. Kaput J, Rodriguez RL (Eds). John Wiley and Sons, NJ, USA, 469 (2006).
4. Nebert DW: Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin. Genet. 56(4), 247-258 (1999).
5. Mutch DM, Wahli W, Williamson G: Nutrigenomics and nutrigenetics: the emerging faces of nutrition. FASEB J. 19(12), 1602-1616 (2005).
6. Jorde LB, Wooding SP: Genetic variation, classification and 'race'. Nat. Genet. 36(Suppl. 1), S28-S33 (2004).
7. Hinds DA, Stuve LL, Nilsen GB et al.: Whole-genome patterns of common DNA variation in three human populations. Science 307(5712), 1072-1079 (2005).
8. Burchard EG, Avila PC, Nazario S et al.: Lower bronchodilator responsiveness in Puerto Rican than in Mexican subjects with asthma. Am. J. Respir. Crit. Care Med. 169(3), 386-392 (2004).
9. Rosskopf D, Manthey I, Siffert W: Identification and ethnic distribution of major haplotypes in the gene GNB3 encoding the G-protein β3 subunit. Pharmacogenetics 12(3), 209-220 (2002).
10. Xie HG, Kim RB, Wood AJ, Stein CM: Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41, 815-850 (2001).
11. Chiu S, Diament AL, Fisler JS, Warden CH: Gene-gene epistasis and gene environment interactions influence diabetes and obesity. In: Nutritional Genomics. Discovering the Path to Personalized Nutrition. Kaput J, Rodriguez RL (Eds). John Wiley and Sons, NJ, USA. 135-152 (2006).
12. Cooney CA: Maternal nutrition: nutrients and control of expression. In: Nutritional Genomics. Discovering the Path to Personalized Nutrition. Kaput J, Rodriguez RL (Eds). John Wiley and Sons, NJ, USA 219-254 (2006).
13. Enattah NS, Sahi T, Savilahti E, Terwilliger JD, Peltonen L, Jarvela I: Identification of a variant associated with adult-type hypolactasia. Nat. Genet. 30(2), 233-237 (2002).
14. Hollox EJ, Poulter M, Wang Y, Krause A, Swallow DM: Common polymorphism in a highly variable region upstream of the human lactase gene affects DNA-protein interactions. Eur. J. Hum. Genet. 7(7), 791-800 (1999).
15. Tishkoff SA, Reed FA, Ranciaro A et al.: Convergent adaptation of human lactase persistence in Africa and Europe. Nat. Genet. 39(1), 31-40 (2007).
16. Swallow DM: Genetics of lactase persistence and lactose intolerance. Annu. Rev. Genet 37, 197-219 (2003).
17. Ekins S, Nikolsky Y, Nikolskaya T: Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharmacol. Sci. 26(4), 202-209 (2005).
18. Kaput J: Diet-disease gene interactions. Nutrition 20(1), 26-31 (2004).
19. Hartman JL, Garvik B, Hartwell L: Principles for the buffering of genetic variation. Science 291(5506), 1001-1004 (2001).
20. Carlborg O, Haley CS: Epistasis: too often neglected in complex trait studies? Nat. Rev. Genet. 5(8), 618-625 (2004).
21. Moore JH: The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum. Hered. 56(1-3), 73-82 (2003).
22. van Ommen B, Stierum R: Nutrigenomics: exploiting systems biology in the nutrition and health arena. Curr. Opin. Biotechnol. 13(5), 517-521 (2002).
23. Ordovas JM: The quest for cardiovascular health in the genomic era: nutrigenetics and plasma lipoproteins. Proc. Nutr. Soc. 63(1), 145-152 (2004).
24. Corella D, Ordovas JM: The metabolic syndrome: a crossroad for genotype-phenotype associations in atherosclerosis. Curr. Atheroscler. Rep. 6(3), 186-196 (2004).
25. Togawa K, Moritani M, Yaguchi H, Itakura M: Multidimensional genome scans identify the combinations of genetic loci linked to diabetes-related phenotypes in mice. Hum. Mol. Genet. 15(1), 113-128 (2006).
26. Klos KLE, Kardia SLR, Hixson JE et al.: Linkage analysis of plasma ApoE in three ethnic groups: multiple genes with context-dependent effects. Ann. Hum. Genet. 69, 157-167 (2005).
27. Suarez-Kurtz G, Pena SD: Pharmacogenomics in the Americas: the impact of genetic admixture. Curr. Drug Targets 7(12), 1649-1658 (2006).
28. Helgadottir A, Manolescu A, Helgason A et al.: A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat. Genet. 38(1), 68-74 (2006).
29. Kelley DS: Modulation of human immune and inflammatory responses by dietary fatty acids. Nutrition 17(7-8), 669-673 (2001).
30. Campbell CD, Ogburn EL, Lunetta KL et al.: Demonstrating stratification in a European American population. Nat. Genet. 37(8), 868-872 (2005).
31. Sladek R, Rocheleau G, Rung J et al.: A genome-wide association study identifies novel risk loci for Type 2 diabetes. Nature 445(7130), 881-885 (2007).
32. Helgason A, Yngvadottir B, Hrafnkelsson B, Gulcher J, Stefansson K: An Icelandic example of the impact of population structure on association studies. Nat. Genet. 37(1), 90-95 (2005).
33. Tsai HJ, Kho JY, Shaikh N et al.: Admixture-matched case-control study: a practical approach for genetic association studies in admixed populations. Hum. Genet. 118(5), 626-639 (2006).
34. Tang H, Coram M, Wang P, Zhu X, Risch N: Reconstructing genetic ancestry blocks in admixed individuals. Am. J. Hum. Genet. 79(1), 1-12 (2006).
35. Choudhry S, Coyle NE, Tang H et al.: Population stratification confounds genetic association studies among Latinos. Hum. Genet. 118(5), 652-664 (2006).
36. Yang N, Li H, Criswell LA et al.: Examination of ancestry and ethnic affiliation using highly informative diallelic DNA markers: application to diverse and admixed populations and implications for clinical epidemiology and forensic medicine. Hum. Genet. 118(3-4), 382-392 (2005).
37. Tsai HJ, Choudhry S, Naqvi M, Rodriguez-Cintron W, Burchard EG, Ziv E: Comparison of three methods to estimate genetic ancestry and control for stratification in genetic association studies among admixed populations. Hum. Genet. 118(3-4), 424-433 (2005).
38. Fowler AM, Alarid ET: Dynamic control of nuclear receptor transcription. Sci. STKE 2004(256), PE51 (2004).
39. Morgan HD, Santos F, Green K, Dean W, Reik W: Epigenetic reprogramming in mammals. Hum. Mol. Genet. 14(1), R47-R58 (2005).
40. Jiang YH, Bressler J, Beaud AL et al.: Epigenetics and human disease. Annu. Rev. Genomics Hum. Genet. 5, 479-510 (2004).
41. Delaval K, Feil R: Epigenetic regulation of mammalian genomic imprinting. Curr. Opin. Genet. Dev. 14(2), 188-195 (2004).
42. Fenech M: The Genome Health Clinic and Genome Health Nutrigenomics concepts: diagnosis and nutritional treatment of genome and epigenome damage on an individual basis. Mutagenesis 20(4), 255-269 (2005).
43. Dolinoy DC, Weidman JR, Waterland RA, Jirtle RL: Maternal genistein alters coat color and protects Avy mouse offspring from obesity by modifying the fetal epigenome. Environ. Health Perspect. 114(4), 567-572 (2006).
44. Picard F, Kurtev M, Chung N et al.: Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ. Nature 429(6993), 771-776 (2004).
45. Gallou-Kabani C, Junien C: Nutritional epigenomics of metabolic syndrome: new perspective against the epidemic. Diabetes 54(7), 1899-1906 (2005).
46. Sneider TW, Teague WM, Rogachevsky LM: S-adenosylmethionine: DNA-cytosine 5-methyltransferase from a Novikoff rat hepatoma cell line. Nucleic Acids Res. 2(10), 1685-1700 (1975).
47. Mason JB: Biomarkers of nutrient exposure and status in one-carbon (methyl) metabolism. J. Nutr. 133(Suppl. 3), S941-S947 (2003).
48. Stover PJ, Garza C: Bringing individuality to public health recommendations. J. Nutr. 132(8 Suppl.), S2476-S2480 (2002).
49. Blander G, Guarente L: The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 73, 417-435 (2004).
50. Hsiao PW, Deroo BJ, Archer TK: Chromatin remodeling and tissue-selective responses of nuclear hormone receptors. Biochem. Cell Biol. 80(3), 343-351 (2002).
51. Eberharter A, Becker PB: Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep. 3(3), 224-229 (2002).
52. Cho KS, Elizondo LI, Boerkoel CF: Advances in chromatin remodeling and human disease. Curr. Opin. Genet. Dev. 14(3), 308-315 (2004).
53. Geiman TM, Robertson KD: Chromatin remodeling, histone modifications, and DNA methylation - how does it all fit together? J. Cell Biochem. 87(2), 117-125 (2002).
54. McMillen IC, Robinson JS: Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. Physiol. Rev. 85(2), 571-633 (2005).
55. Nestel P: Nutritional aspects in the causation and management of the metabolic syndrome. Endocrinol. Metab. Clin. North Am. 33(3), 483-492 (2004).
56. Bonnefont-Rousselot D: The role of antioxidant micronutrients in the prevention of diabetic complications. Treat. Endocrinol. 3(1), 41-52 (2004).
57. Biesalski HK: Diabetes preventive components in the Mediterranean diet. Eur. J. Nutr. 43(Suppl. 1), I26-I30 (2004).
58. Neff LM: Evidence-based dietary recommendations for patients with Type 2 diabetes mellitus. Nutr. Clin. Care 6(2), 51-61 (2003).
59. Hung T, Sievenpiper JL, Marchie A, Kendall CW, Jenkins DJ: Fat versus carbohydrate in insulin resistance, obesity, diabetes and cardiovascular disease. Curr. Opin. Clin. Nutr. Metab. Care 6(2), 165-176 (2003).
60. Schuster GU: Nutrients and gene expression. In: Nutritional Genomics. Discovering the Path to Personalized Nutrition. Kaput J, Rodriguez RL (Eds). John Wiley and Sons, NJ, USA, 153-176 (2006).
61. Pike AC, Brzozowski AM, Hubbard RE et al.: Structure of the ligand-binding domain of oestrogen receptor β in the presence of a partial agonist and a full antagonist. EMBO J. 18(17), 4608-4618 (1999).
62. Kuiper GG, Carlsson B, Grandien K et al.: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138(3), 863-870 (1997).
63. Naciff JM, Jump ML, Torontali SM et al.: Gene expression profile induced by 17α-ethynyl estradiol, bisphenol A, and genistein in the developing female reproductive system of the rat. Toxicol. Sci. 68(1), 184-199 (2002).
64. Brandenberger AW, Tee MK, Lee JY, Chao V, Jaffe RB: Tissue distribution of estrogen receptors α (ER-α) and β (ER-β) mRNA in the midgestational human fetus. J. Clin. Endocrinol. Metab. 82(10), 3509-3512 (1997).
65. Kuiper GG, Shughrue PJ, Merchenthaler I, Gustafsson JA: The estrogen receptor β subtype: a novel mediator of estrogen action in neuroendocrine systems. Front. Neuroendocrinol. 19(4), 253-286 (1998).
66. Kousidou O, Tzanakakis GN, Karamanos NK: Effects of the natural isoflavonoid genistein on growth, signaling pathways and gene expression of matrix macromolecules by breast cancer cells. Mini Rev. Med. Chem. 6(3), 331-337 (2006).
67. Moore LB, Goodwin B, Jones SA et al.: St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl Acad. Sci. USA 97(13), 7500-7502 (2000).
68. Watkins RE, Maglich JM, Moore LB et al.: 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 42(6), 1430-1438 (2003).
69. Tirona RG, Leake BF, Podust LM, Kim RB: Identification of amino acids in rat pregnane X receptor that determine species-specific activation. Mol. Pharmacol. 65(1), 36-44 (2004).
70. Rebbeck TR, Spitz M, Wu X: Assessing the function of genetic variants in candidate gene association studies. Nat. Rev. Genet. 5(8), 589-597 (2004).
71. Jones SA, Moore LB, Shenk JL et al.: The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 14(1), 27-39 (2000).
72. Chambrier C, Bastard JP, Rieusset J et al.: Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor γ. Obes. Res. 10(6), 518-525 (2002).
73. 2 derivatives really playing the part? Cell Signal. 14(7), 573-583 (2002).
74. Fyffe SA, Alphey MS, Buetow L et al.: Recombinant human PPAR-β/δ ligand-binding domain is locked in an activated conformation by endogenous fatty acids. J. Mol. Biol. 356(4), 1005-1013 (2006).
75. Stumvoll M, Goldstein BJ, van Haeften TW: Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365(9467), 1333-1346 (2005).
76. Rosenzweig JL, Weinger K, Poirier-Solomon L, Rushton M: Use of a disease severity index for evaluation of healthcare costs and management of comorbidities of patients with diabetes mellitus. Am. J. Manag. Care 8(11), 950-958 (2002).
77. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO: Glycemic control from 1988 to 2000 among U.S. adults diagnosed with Type 2 diabetes: a preliminary report. Diabetes Care 27(1), 17-20 (2004).
78. Kwon G, Marshall CA, Pappan KL, Remedi MS, McDaniel ML: Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets. Diabetes 53(Suppl. 3), S225-S232 (2004).
79. Nauck MA, Meier JJ: Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul. Pept. 128(2), 135-148 (2005).
80. Babenko AP, Polak M, Cave H et al.: Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N. Engl. J. Med. 355(5), 456-466 (2006).
81. Sperling MA: ATP-sensitive potassium channels - neonatal diabetes mellitus and beyond. N. Engl. J. Med. 355(5), 507-510 (2006).
82. Proks P, Lippiat JD: Membrane ion channels and diabetes. Curr. Pharm. Des. 12(4), 485-501 (2006).
83. Tsukahara T, Tsukahara R, Yasuda S et al.: Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor γ. J. Biol. Chem. 281(6), 3398-3407 (2006).
84. Nolte RT, Wisely GB, Westin S et al.: Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395(6698), 137-143 (1998).
85. Spiller HA, Sawyer TS: Toxicology of oral antidiabetic medications. Am. J. Health Syst. Pharm. 63(10), 929-938 (2006).
86. Jain KK: Applications of AmpliChip CYP450. Mol. Diagn. 9(3), 119-127 (2005).
87. Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J: Effect of genetic polymorphisms in cytochrome p450 (CYP)2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin. Pharmacokinet. 44(12), 1209-1225 (2005).
88. Kirchheiner J, Thomas S, Bauer S et al.: Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin. Pharmacol. Ther. 80(6), 657-667 (2006).
89. Corella D, Lai CQ, Demissie S et al.: APOA5 gene variation modulates the effects of dietary fat intake on body mass index and obesity risk in the Framingham Heart Study. J. Mol. Med. 85(2), 119-128 (2007).
90. Ordovas JM, Corella D: Genetic variation and lipid metabolism: modulation by dietary factors. Curr. Cardiol. Rep. 7(6), 480-486 (2005).
91. Florez JC, Burtt N, de Bakker PI et al.: Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 53(5), 1360-1368 (2004).
92. Ioannidis JP: Why most published research findings are false. PLoS Med 2(8), E124 (2005).
93. Ioannidis JPA, Gwinn M, Little J et al.; The Human Genome Epidemiology Network and the Network of Investigator: a road map for efficient and reliable human genome epidemiology. Nat. Genet. 38(1), 3-5 (2006).
94. Corella D, Ordovas JM: Single nucleotide polymorphisms that influence lipid metabolism: interaction with dietary factors. Annu. Rev. Nutr. 25, 341-390 (2005).
95. Corella D, Ordovas JM: Integration of environment and disease into 'omics' analysis. Curr. Opin. Mol. Ther. 7(6), 569-576 (2005).
96. Ordovas JM, Corella D: Gene-environment interactions: defining the playfield. In: Nutritional Genomics. Discovering the Path to Personalized Nutrition. Kaput J, Rodriguez RL (Eds). John Wiley and Sons, NJ, USA, 57-76 (2006).
97. 2 is a ligand for the adipocyte determination factor PPAR γ. Cell 83(5), 803-812 (1995).
98. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83(5), 813-819 (1995).
99. Barger PM, Kelly DP: PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc. Med. 10(6), 238-245 (2000).
100. Boitier E, Gautier JC, Roberts R: Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease. Comp. Hepatol. 2(1), 3 (2003).
101. Desvergne B, IJpenberg A, Devchand PR, Wahli W: The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signalling. J. Steroid Biochem. Mol. Biol. 65(1-6), 65-74 (1998).
102. Escher P, Wahli W: Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat. Res. 448(2), 121-138 (2000).
103. Kota BP, Huang TH, Roufogalis BD: An overview on biological mechanisms of PPARs. Pharmacol. Res. 51(2), 85-94 (2005).
104. Schoonjans K, Staels B, Auwerx J: Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37(5), 907-925 (1996).
105. Smith SA: Peroxisome proliferator-activated receptors and the regulation of mammalian lipid metabolism. Biochem. Soc. Trans. 30(Pt 6), 1086-1090 (2002).
106. Clarke SD: Polyunsaturated fatty acid regulation of gene transcription: a molecular mechanism to improve the metabolic syndrome. J. Nutr. 131(4), 1129-1132 (2001).
107. Kaput J, Noble J, Hatipoglu B, Kohrs K, Dawson K, Bartholomew A: Application of nutrigenomic concepts to Type 2 diabetes mellitus. Nutr. Metab. Cardiovasc. Dis. 17(2), 89-103 (2007).
108. Padmanabhan B, Tong KI, Ohta T et al.: Structural basis for defects of KEAP1 activity provoked by its point mutations in lung cancer. Mol. Cell 21(5), 689-700 (2006).
109. Sampson MJ, Hughes DA: Chromosomal telomere attrition as a mechanism for the increased risk of epithelial cancers and senescent phenotypes in Type 2 diabetes. Diabetologia 49(8), 1726-1731 (2006).
110. Frisard M, Ravussin E: Energy metabolism and oxidative stress: impact on the metabolic syndrome and the aging process. Endocrine 29(1), 27-32 (2006).
111. Schrauwen P, Hesselink MK: Oxidative capacity, lipotoxicity, and mitochondrial damage in Type 2 diabetes. Diabetes 53(6), 1412-1417 (2004).
112. Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 52(1), 1-8 (2003).
113. Kaput J, Klein KG, Reyes EJ et al.: Identification of genes contributing to the obese yellow Avy phenotype: caloric restriction, genotype, diet x genotype interactions. Physiol. Genomics 18(3), 316-324 (2004).
114. Swartz DA, Park EI, Visek WJ, Kaput J: The ε subunit gene of murine F1F0-ATP synthase. Genomic sequence, chromosomal mapping, and diet regulation. J. Biol. Chem. 271(34), 20942-20948 (1996).
115. Kaput J, Swartz D, Paisley E, Mangian H, Daniel WL, Visek WJ: Diet-disease interactions at the molecular level: an experimental paradigm. J. Nutr. 124(8 Suppl.), S1296-S1305 (1994).
116. Kaput J, Ordovas JM, Ferguson L et al.: The case for strategic international alliances to harness nutritional genomics for public and personal health. Br. J. Nutr. 94(5), 623-632 (2005).
117. Roweis ST, Saul LK: Nonlinear dimensionality reduction by locally linear embedding. Science 290(5500), 2323-2326 (2000).
118. Tenenbaum JB, de Silva V, Langford JC: A global geometric framework for nonlinear dimensionality reduction. Science 290(5500), 2319-2323 (2000).
119. Azuaje F, Wang H, Chesneau A: Non-linear mapping for exploratory data analysis in functional genomics. BMC Bioinformatics 6, 13 (2005).
120. Priami C, Quaglia P: Modelling the dynamics of biosystems. Brief Bioinform. 5(3), 259-269 (2004).
121. Kaput J, aD K: Dimensionality reduction of nutrigenomic data sets in the study of Type 2 diabetes mellitus. Mutat. Res. (2007) (In Press).
122. Dawson K, Rodriguez RL, Malyj W: Sample phenotype clusters in high-density oligonucleotide microarray data sets are revealed using Isomap, a nonlinear algorithm. BMC Bioinformatics 6, 195 (2005).
123. Dawson K, Rodrigueez RL, Hawkes WC, Malyj W: Biocomputation and the analysis of complex data sets in nutritional genomics. In: Nutritional Genomics. Discovering the Path to Personalized Nutrition. Kaput J, Rodriguez RL (Eds). John Wiley and Sons, NJ, USA, 375-402 (2006).
124. Motsinger AA, Ritchie MD: Multifactor dimensionality reduction: an analysis strategy for modelling and detecting gene-gene interactions in human genetics and pharmacogenomics studies. Hum. Genomics 2(5), 318-328 (2006).
125. Bishop-Bailey D: Peroxisome proliferator-activated receptors in the cardiovascular system. Br. J. Pharmacol. 129(5), 823-834 (2000).
126. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20(5), 649-688 (1999).
127. Yamamoto J, Kageyama S, Nemoto M et al.: PPARγ2 pro12Ala polymorphism and insulin resistance in Japanese hypertensive patients. Hypertens. Res. 25(1), 25-29 (2002).
128. Ylitalo K, Nuotio I, Viikari J, Auwerx J, Vidal H, Taskinen MR: C3, hormonesensitive lipase, and peroxisome proliferator-activated receptor γ expression in adipose tissue of familial combined hyperlipidemia patients. Metabolism 51(5), 664-670 (2002).
129. Auwerx J, Martin G, Guerre-Millo M, Staels B: Transcription, adipocyte differentiation, and obesity. J. Mol. Med. 74(7), 347-352 (1996).
130. Redonnet A, Bonilla S, Noel-Suberville C et al.: Relationship between peroxisome proliferator-activated receptor γ and retinoic acid receptor α gene expression in obese human adipose tissue. Int. J. Obes. Relat. Metab. Disord. 26(7), 920-977 (2002).
131. Muller YL, Bogardus C, Beamer BA, Shuldiner AR, Baier LJ: A functional variant in the peroxisome proliferator-activated receptor γ2 promoter is associated with predictors of obesity and Type 2 diabetes in Pima Indians. Diabetes 52(7), 1864-1871 (2003).
132. Orio F, Jr, Matarese G, Di Biase S et al.: Exon 6 and 2 peroxisome proliferator-activated receptor-γ polymorphisms in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88(12), 5887-5892 (2003).
133. Damcott CM, Moffett SP, Feingold E et al.: Genetic variation in fatty acid-binding protein-4 and peroxisome proliferator-activated receptor γ interactively influence insulin sensitivity and body composition in males. Metabolism 53(3), 303-309 (2004).
134. Buzzetti R, Petrone A, Caiazzo AM et al.: PPAR-γ2 Pro12Ala variant is associated with greater insulin sensitivity in childhood obesity. Pediatr. Res. 57(1), 138-140 (2005).
135. Zouari Bouassida K, Chouchane L, Jellouli K et al.: The peroxisome proliferator activated receptorγ2 (PPARγ2) Pro12Ala variant: lack of association with Type 2 diabetes in obese and non obese Tunisian patients. Diabetes Metab. 31(2), 119-123 (2005).
136. Farrow B, Evers BM: Activation of PPARγ increases PTEN expression in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 301(1), 50-53 (2003).
137. Eibl G, Wente MN, Reber HA, Hines OJ: Peroxisome proliferator-activated receptor γ induces pancreatic cancer cell apoptosis. Biochem. Biophys. Res. Commun. 287(2), 522-529 (2001).
138. Florez JC, Hirschhorn J, Altshuler D: The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu. Rev. Genomics Hum. Genet. 4, 257-291 (2003).
139. Chiu YF, Chuang LM, Hsiao CF et al.: An autosomal genome-wide scan for loci linked to pre-diabetic phenotypes in nondiabetic Chinese subjects from the Stanford Asia-Pacific Program of Hypertension and Insulin Resistance Family Study. Diabetes 54(4), 1200-1206 (2005).
140. Foretz M, Pacot C, Dugail I et al.: ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. 19(5), 3760-3768 (1999).
141. Pawlak DB, Kushner JA, Ludwig DS: Effects of dietary glycaemic index on adiposity, glucose homoeostasis, and plasma lipids in animals. Lancet 364(9436), 778-785 (2004).
142. Mantzoros CS, Williams CJ, Manson JE, Meigs JB, Hu FB: Adherence to the Mediterranean dietary pattern is positively associated with plasma adiponectin concentrations in diabetic women. Am. J. Clin. Nutr. 84(2), 328-235 (2006).
143. Cardillo S, Seshadri P, Iqbal N: The effects of a low-carbohydrate versus low-fat diet on adipocytokines in severely obese adults: three-year follow-up of a randomized trial. Eur. Rev. Med. Pharmacol. Sci. 10(3), 99-106 (2006).
144. Butte NF, Comuzzie AG, Cai G, Cole SA, Mehta NR, Bacino CA: Genetic and environmental factors influencing fasting serum adiponectin in Hispanic children. J. Clin. Endocrinol. Metab. 90(7), 4170-4176 (2005).
145. Kadowaki T, Yamauchi T: Adiponectin and adiponectin receptors. Endocr. Rev. 26(3), 439-451 (2005).
146. Eisenach JH, Schroeder DR, Pike TL et al.: Dietary sodium restriction and β2-adrenergic receptor polymorphism modulate cardiovascular function in humans. J. Physiol. 574(Pt 3), 955-965 (2006).
147. Straus DS: Nutritional regulation of visceral markers in rat liver and cultured hepatoma cells. Clin. Chem. Lab. Med. 40(12), 1274-1280 (2002).
148. Showers D: Strategies to improve albumin in patients on peritoneal dialysis. Nephrol. Nurs. J. 31(5), 592-593 (2004).
149. Murray M: Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. Curr. Drug Metab. 7(1), 67-81 (2006).
150. Feierman DE, Melinkov Z, Nanji AA: Induction of CYP3A by ethanol in multiple in vitro and in vivo models. Alcohol Clin. Exp. Res. 27(6), 981-988 (2003).
151. Liu DY, Yang M, Zhu HJ, Zheng YF, Zhu XQ: Human pregnane X receptor-mediated transcriptional regulation of cytochrome P450 3A4 by some phytochemicals. Zhejiang Da Xue Xue Bao Yi Xue Ban 35(1), 8-13 (2006).
152. Felder RA, Jose PA: Mechanisms of disease: the role of GRK4 in the etiology of essential hypertension and salt sensitivity. Nat. Clin. Pract. Nephrol. 2(11), 637-650 (2006).
153. Kovar J, Fejfarova V, Pelikanova T, Poledne R: Hyperglycemia downregulates total lipoprotein lipase activity in humans. Physiol. Res. 53(1), 61-68 (2004).
154. Sanders TA: Dietary fat and postprandial lipids. Curr. Atheroscler. Rep. 5(6), 445-451 (2003).
155. Kudo T, Nakayama E, Suzuki S, Akiyama M, Shibata S: Cholesterol diet enhances daily rhythm of Pai-1 mRNA in the mouse liver. Am J. Physiol. Endocrinol. Metab. 287(4), E644-E651 (2004).
156. Takahara T, Hara K, Yonezawa K, Sorimachi H, Maeda T: Nutrient-dependent multimerization of the mammalian target of rapamycin through the N-terminal HEAT repeat region. J. Biol. Chem. 281(39), 28605-28614 (2006).
157. Jump DB: Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr. Opin. Lipidol. 13(2), 155-164 (2002).
158. Memisoglu A, Hu FB, Hankinson SE et al.: Interaction between a peroxisome proliferator-activated receptor γ gene polymorphism and dietary fat intake in relation to body mass. Hum. Mol. Genet. 12(22), 2923-2929 (2003).
159. Roberts CK, Liang K, Barnard RJ, Kim CH, Vaziri ND: HMG-CoA reductase, cholesterol 7α-hydroxylase LDL receptor SR-B1, and ACAT in diet-induced syndrome X. Kidney Int. 66(4), 1503-1511 (2004).
160. Spady DK, Kearney DM, Hobbs HH: Polyunsaturated fatty acids up-regulate hepatic scavenger receptor B1 (SR-BI) expression and HDL cholesteryl ester uptake in the hamster. J. Lipid Res. 40(8), 1384-1394 (1999).
161. Miles EA, Wallace FA, Calder PC: Reduction of scavenger receptor expression and function by dietary fish oil is accompanied by a reduction in scavenger receptor mRNA. Lipids 34(Suppl.), S215-S216 (1999).
162. Ukkola O, Tremblay A, Sun G, Chagnon YC, Bouchard C: Genetic variation at the uncoupling protein 1, 2 and 3 loci and the response to long-term overfeeding. Eur. J. Clin. Nutr. 55(11), 1008-1015 (2001).
163. Darimont C, Avanti O, Zbinden I et al.: Liver X receptor preferentially activates de novo lipogenesis in human preadipocytes. Biochimie 88(3-4), 309-318 (2006).
164. Maeda N, Takahashi M, Funahashi T et al.: PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50(9), 2094-2099 (2001).
165. Sun X, Han R, Wang Z, Chen Y: Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Diabetologia 49(6), 1303-1310 (2006).
166. Chana RS, Brunskill NJ: Thiazolidinediones inhibit albumin uptake by proximal tubular cells through a mechanism independent of peroxisome proliferator activated receptor γ. Am. J. Nephrol. 26(1), 67-74 (2006).
167. Sahi J, Black CB, Hamilton GA et al.: Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab. Dispos. 31(4), 439-446 (2003).
168. Arlt W, Auchus RJ, Miller WL: Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3β-hydroxysteroid dehydrogenase. J. Biol. Chem. 276(20), 16767-16771 (2001).
169. Trivedi M, Lokhandwala MF: Rosiglitazone restores renal D1A receptor-Gs protein coupling by reducing receptor hyperphosphorylation in obese rats. Am J. Physiol. Renal Physiol. 289(2), F298-F304 (2005).
170. Deng T, Shan S, Li PP et al.: Peroxisome proliferator-activated receptor-γ transcriptionally up-regulates hormone-sensitive lipase via the involvement of specificity protein-1. Endocrinology 147(2), 875-884 (2006).
171. Teruel T, Hernandez R, Rial E, Martin-Hidalgo A, Lorenzo M: Rosiglitazone up-regulates lipoprotein lipase, hormone-sensitive lipase and uncoupling protein-1, and down-regulates insulin-induced fatty acid synthase gene expression in brown adipocytes of Wistar rats. Diabetologia 48(6), 1180-1188 (2005).
172. Liu HB, Hu YS, Medcalf RL, Simpson RW, Dear AE: Thiazolidinediones inhibit TNFα induction of PAI-1 independent of PPARγ activation. Biochem. Biophys. Res. Commun. 334(1), 30-37 (2005).
173. Cho DH, Choi YJ, Jo SA et al.: Troglitazone acutely inhibits protein synthesis in endothelial cells via a novel mechanism involving protein phosphatase 2A-dependent p70 S6 kinase inhibition. Am. J. Physiol. Cell Physiol 291(2), C317-C326 (2006).
174. Rival Y, Stennevin A, Puech L et al.: Human adipocyte fatty acid-binding protein (aP2) gene promoter-driven reporter assay discriminates nonlipogenic peroxisome proliferator-activated receptor γ ligands. J. Pharmacol. Exp. Ther. 311(2), 467-475 (2004).
175. Wurch T, Junquero D, Delhon A, Pauwels J: Pharmacological analysis of wild-type α, γ and δ subtypes of the human peroxisome proliferator-activated receptor. Naunyn Schmiedebergs Arch. Pharmacol. 365(2), 133-140 (2002).
176. Aiello A, Pandini G, Frasca F et al.: Peroxisomal proliferator-activated receptor-γ agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 147(9), 4463-4475 (2006).
177. Lee SY, Hur GY, Jung KH et al.: PPAR-γ agonist increase gefitinib's antitumor activity through PTEN expression. Lung Cancer 51(3), 297-301 (2006).
178. Liu G, Moon TW, Metcalfe CD, Lee LE, Trudeau VL: A teleost in vitro reporter gene assay to screen for agonists of the peroxisome proliferator-activated receptors. Environ. Toxicol. Chem. 24(9), 2260-2266 (2005).
179. Rendell M: The role of sulphonylureas in the management of Type 2 diabetes mellitus. Drugs 64(12), 1339-1358 (2004).
180. Deplanque D: Cell protection through PPAR nuclear receptor activation. Therapie 59(1), 25-29 (2004).
181. 2, ligands of the peroxisome proliferator-activated receptor-γ (PPAR-γ), reduce ischaemia/ reperfusion injury of the gut. Br. J. Pharmacol. 140(2), 366-376 (2003).
182. Davies GF, Khandelwal RL, Wu L, Juurlink BH, Roesler WJ: Inhibition of
183. Murphy GJ, Holder JC: PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol. Sci. 21(12), 469-474 (2000).
184. Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature 405(6785), 421-424 (2000).
185. Shao D, Rangwala SM, Bailey ST, Krakow SL, Reginato MJ, Lazar MA: Interdomain communication regulating ligand binding by PPAR-γ. Nature 396(6709), 377-380 (1998).
186. Llaverias G, Rebollo A, Pou J et al.: Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem. Pharmacol. 71(5), 605-614 (2006).
187. Lopez-Solache I, Marie V, Vignault E, Camirand A, Silva JE: Regulation of uncoupling protein-2 mRNA in L6 myotubules: I: Thiazolidinediones stimulate uncoupling protein-2 gene expression by a mechanism requiring ongoing protein synthesis and an active mitogen-activated protein kinase. Endocrine 19(2), 197-208 (2002).
188. Digby JE, Crowley VE, Sewter CP, Whitehead JP, Prins JB, O'Rahilly S: Depot-related and thiazolidinedione-responsive expression of uncoupling protein 2 (UCP2) in human adipocytes. Int. J. Obes. Relat. Metab. Disord. 24(5), 585-592 (2000).
189. Emilsson V, O'Dowd J, Wang S et al.: The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. Metabolism 49(12), 1610-1615 (2000).
190. Wielinga PR, van der Heijden I, Reid G, Beijnen JH, Wijnholds J, Borst P: Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J. Biol. Chem. 278(20), 17664-17671 (2003).
191. Reid G, Wielinga P, Zelcer N et al.: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc. Natl Acad. Sci. USA 100(16), 9244-9249 (2003).
192. 2 and laminar fluid shear stress stabilize c-IAP1 in vascular endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 285(1), H38-H46 (2003).
193. Hashimoto K, Ethridge RT, Evers BM: Peroxisome proliferator-activated receptor γ ligand inhibits cell growth and invasion of human pancreatic cancer cells. Int. J. Gastrointest. Cancer 32(1), 7-22 (2002).
194. Wen Y, Gu J, Knaus UG, Thomas L, Gonzales N, Nadler JL: Evidence that 12-lipoxygenase product 12-hydroxyeicosatetraenoic acid activates p21-activated kinase. Biochem. J. 349(Pt 2), 481-487 (2000).
195. 2) and N-(4-hydroxyphenyl)-retinamide (4HPR) is associated with enhanced ceramide production. J. Steroid Biochem. Mol. Biol. 94(1-3), 159-165 (2005).
196. 2 metabolites inhibit aromatase activity by redox-sensitive mechanisms: potential implications for breast cancer therapy. Int. J. Cancer 103(5), 600-605 (2003).
197. Obinata H, Hattori T, Nakane S, Tatei K, Izumi T: Identification of 9-hydroxyoctadecadienoic acid and other oxidized free fatty acids as ligands of the G protein-coupled receptor G2A. J. Biol. Chem. 280(49), 40676-40683 (2005).
198. 2 and its inhibition by intracellular glutathione. Biochem. Pharmacol. 45(12), 2457-2464 (1993).
199. Levonen AL, Landar A, Ramachandran A et al.: Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem. J. 378(Pt 2), 373-382 (2004).
200. Hosoya T, Maruyama A, Kang MI et al.: Differential responses of the Nrf2-Keap1 system to laminar and oscillatory shear stresses in endothelial cells. J. Biol. Chem. 280(29), 27244-27250 (2005).
201. 2. Mol. Cell Biol. 24(1), 36-45 (2004).
202. Mandal AK, Zhang Z, Kim SJ, Tsai PC, Mukherjee AB: Yin-yang: balancing act of prostaglandins with opposing functions to regulate inflammation. J. Immunol. 175(10), 6271-6273 (2005).
203. Boller YC, Brandes LM, Russell RL, Lin ZP, Patierno SR, Kennedy KA: Prostaglandin A1 inhibits stress-induced NF-κB activation and reverses resistance to topoisomerase II inhibitors. Oncol. Res. 12(9-10), 383-395 (2000).
204. He JK, Gu ZL, Fan PS: Inhibitory effects of prostaglandin A1 on apoptosis of rat cardiac microvascular endothelial cells was mediated by NF-κB. Acta Pharmacol. Sin. 23(4), 331-335 (2002).